Skip to main content

Table 1 Baseline clinical characteristics and laboratory findings in RA patients with different response to anti-TNF-α therapy

From: Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy

 

RA with anti-TNF-α Rx.

Healthy control

 

Moderate-good responders (n= 36)

Non- responders (n= 12)

(n= 12)

Mean age, years

50.4 ± 14.5

49.3 ± 10.8

47.6 ± 8.1

Female (%)

29 (80.6%)

10 (83.3%)

10 (83.3%)

Disease duration, years

5.44 ± 2.42

5.37 ± 2.37

NA

RF positivity (%)

30 (83.3%)

11 (91.6%)

NA

Anti-CCP positivity (%)

29 (80.6%)

10 (83.3%)

NA

ESR (mm/1st hr)

48.9 ± 25.4

63.8 ± 24.4

NA

DAS-28

7.18 ± 0.74

7.33 ± 0.94

NA

Daily steroid dose (mg)

6.5 ± 2.1

6.9 ± 2.4

NA

TNF-α inhibitors

   

   Etanercept (n = 14)

10 (71.4%)

4 (28.6%)

NA

   Adalimumab (n = 34)

26 (76.5%)

8 (23.5%)

NA

Used DMARDs

   

   Methotrexate

33 (91.7%)

11 (91.6%)

NA

   Sulfasalazine

31 (86.1%)

10 (83.3%)

NA

   Hydroxychloroqine

32 (88.9%)

10 (83.3%)

NA

   Ciclosporine

14 (38.9%)

5 (41.7%)

NA

  1. Data are presented as mean ± SD or number (percentage).
  2. RA, rheumatoid arthritis; Anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, disease activity score for 28-joints; DMARDs, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; NA, not applicable; RF, rheumatoid factor; TNF-α, tumor necrosis factor-α.